Cooperative Agreement UG3DA063363
Award Date 9/1/25
Completion Date 8/31/27
Dollars Obligated $2.7M
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
Missouri, USA
Similar Awards
- The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), awarded a $465,750 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Virginia Commonwealth University (VCU). The award will fund research to develop novel mu opioid receptor (MOR) modulators to counteract the effects of synthetic opioids, which are fueling the opioid crisis in the United States. Specifically, the project will design, synthesize, and characterize a...
- This Cooperative Agreement award from the National Institute on Drug Abuse (NIDA), part of the Drug Use and Addiction Research Programs (CFDA 93.279), is supporting Mebias Discovery Inc. in the development of a new chemical entity, MEB-1170, for the treatment of opioid use disorder (OUD). The project will complete preclinical studies in rodents and non-human primates to evaluate the efficacy of MEB-1170 as a maintenance medication for OUD, as well as conduct Phase 1 clinical trials to assess the...
- This federal Project Grant award of $798,828.00 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to discover novel small molecule therapeutics for the safe and effective treatment of opioid use disorder (OUD). The key products and services to be delivered include: The development of an AI platform called M3.AI that will integrate target-based and phenotype-based methodologies to efficiently identify new drug candidates for OUD...
- This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will fund research to investigate the role of cholinergic interneurons in the ventral tegmental area on opioid-related behaviors. The $373,181 grant, awarded on July 15, 2024 with a completion date of June 30, 2027, aims to determine whether mu-opioid receptors on cholinergic interneurons contribute to opioid reward, consumption, and withdrawal, and how...
- This federal Project Grant award of $453,062.00 was provided by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), under the Drug Use and Addiction Research Programs (CFDA 93.279). The award supports research to better understand the cellular mechanisms regulating opioid receptor signaling and the development of pharmacological tolerance, which is a critical challenge in the clinical management of opioid-based pain treatments. The research aims to...
- This Cooperative Agreement award from the National Institute on Drug Abuse (NIDA), part of the Drug Use and Addiction Research Programs (CFDA 93.279), aims to advance the development of DMX-101, a non-addictive, peripherally acting opioid analgesic, as a medication strategy to prevent opioid use disorder in patients with chronic pain. The $1,593,126 project, running from July 2025 to June 2027, will rigorously evaluate DMX-101's ability to effectively manage chronic pain without the risk of...
- This Project Grant award of $398,137 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is for developing high-precision epigenetic therapeutics to address the growing opioid use disorder (OUD) epidemic in the United States. The award will enable Boston Interactome LLC to apply a novel approach targeting protein-protein interactions of the neuronal G9A complex, a key regulator of DFosB expression under chronic opioid exposure....
- This Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) provides $671,732.00 to The Washington University to conduct research on the mechanisms underlying fentanyl-induced cardiorespiratory depression. The project aims to evaluate peripherally-acting mu opioid receptor antagonists as a potential treatment strategy to reverse opioid-induced respiratory depression without precipitating withdrawal or aversion, which is a...
- This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is funding the development of a novel epigenetic regulator as a potential treatment for opioid use disorder (OUD). The grantee, Epivario Inc., a for-profit biotechnology research organization, will screen a new class of ACSS2 inhibitors and evaluate their efficacy in preclinical animal models of OUD. Specifically, the $275,253 award will support...
- The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), awarded a $1,445,752 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to New York University School of Medicine. The grant, titled "Characterizing Complex OUD Care Trajectories and Outcomes Following Acute Service Utilization: A Population-Based Data Linkage Study," aims to apply novel research approaches to better understand real-world opioid use disorder (OUD)...